OncoMatch/Clinical Trials/NCT05640609
Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer
Is NCT05640609 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies Capeox regimen combined with Sintilimab and Bevacizumab for stomach neoplasm.
Treatment: Capeox regimen combined with Sintilimab and Bevacizumab — The median survival time of first-line chemotherapy for advanced gastric cancer is about one year, and the treatment is still facing the bottleneck. This is a one-arm, open and prospective phase II clinical study. Recruit patients who have been diagnosed with advanced or metastatic adenocarcinoma of the stomach and gastroesophageal junction and have not received systematic treatment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Gastric Cancer
Biomarker criteria
Excluded: HER2 (ERBB2) overexpression
HER2 + (or HER2 +) is known to be positive
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: anti-PD-1 therapy
Previously received anti-PD-1 / PD-L1 antibody
Cannot have received: anti-PD-L1 therapy
Previously received anti-PD-1 / PD-L1 antibody
Cannot have received: anti-CTLA-4 therapy
Previously received anti-CTLA-4 antibody
Cannot have received: checkpoint inhibitor
other drugs acting on T-cell co stimulation or examination cell co stimulation or checkpoint pathway
Lab requirements
Blood counts
Hemoglobin ≥ 90 g/L; ANC ≥ 1.5×10^9/L; Platelet count ≥ 75×10^9/L
Kidney function
Creatinine ≤ 1.5×ULN
Liver function
Total bilirubin ≤ 1.5×ULN; AST, ALT ≤ 3×ULN (≤ 5×ULN if liver metastasis)
The function of the main organs is normal ... Hemoglobin ≥ 90 g / L; Absolute neutrophil count (ANC) ≥ 1.5×109/L; Platelet count ≥ 75×109/L; Albumin ≥ 28 g / L; Total bilirubin ≤ 1.5×ULN; AST, ALT ≤ 3×ULN; If there is liver metastasis, AST, ALT ≤ 5×ULN; Creatinine ≤ 1.5×ULN; INR or PT ≤ 1.5×ULN; APTT ≤ 1.5×ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05640609 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Are patients with ERBB2 alterations eligible?
No. ERBB2 overexpression is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages